Abstract 246P
Background
There is limited data to guide axillary surgery after neoadjuvant endocrine therapy (NET). Here we report axillary status, surgery and outcomes among patients (pts) enrolled to the Palbociclib and Endocrine therapy for LObular breast cancer Preoperative Study (PELOPS).
Methods
Women with cT >1.5cm, N0-3, hormone receptor-positive, HER2-negative breast cancer were randomized 2:1 to NET + Palbociclib (Palbo) vs NET for 24 weeks. Node-positive (cN+) disease was biopsy-proven. Axillary surgery (sentinel lymph node biopsy (SLNB) +/- axillary dissection (ALND)) and nodal evaluation (H&E +/- IHC) were not protocolized. Pre-specified exploratory endpoints were ypN+ rates, local-regional recurrence-free interval (LRFI), and breast cancer-specific survival (BCSS), compared by univariate Cox proportional hazards model.
Results
188 pts were analyzed (128 treated with NET + Palbo, 60 NET). Median age was 56.5 yrs (range 32.0-83.0); 82 (43.6%) had lobular cancer, 99 (52.7%) were cN0, 84 (44.7%) cN+, 5 (2.6%) unknown cN. Of pts with known cN/ypN status, rates of ypN+ disease were 37/92 (40.2%) and 68/77 (88.3%) among cN0 and cN+ patients, respectively (14 unknown ypN). After NET + Palbo, 24/63 (38.1%) cN0 pts were ypN+ and 6/55 (10.9%) cN+ pts had a nodal pCR; after NET alone, 13/29 (44.8%) cN0 pts were ypN+ and 3/22 (13.6%) cN+ pts had a nodal pCR (Table). At a median follow-up of 4.65 yrs (IQR 3.66, 5.56), there was no difference in LRFI by treatment arm. Overall, among 108 ypN+ pts, 26 (24.1%) underwent SLNB, 82 (75.9%) ALND, 99 (91.7%) radiation, and there was no difference in LRFI or BCSS based on the performance of SLNB or ALND (unadjusted HR 1.55 [0.30, 7.92], p=0.59 and 1.10 [0.12, 9.96], p=0.934, respectively). Table: 246P
NET + Palbo (N=128) | NET (N=60) | ||||||
pN0 (N=47) | pN+ (N=75) | Unknown (N=6) | pN0 (N=19) | pN+ (N=33) | Unknown (N=8) | ||
cN0 (N=66) | 39 | 24 | 3 | cN0 (N=33) | 16 | 13 | 4 |
cN+ (N=58) | 6 | 49 | 3 | cN+ (N=26) | 3 | 19 | 4 |
Unknown (N=4) | 2 | 2 | 0 | Unknown (N=1) | 0 | 1 | 0 |
Conclusions
The addition of Palbo to NET did not impact pathologic nodal outcomes: nodal pCR rates were 10.9% after NET + Palbo and 13.6% after NET. Among those with ypN+ disease, neither LRFI nor BCSS appears to be impacted by the performance of ALND.
Clinical trial identification
NCT02764541 Dana Farber DFCI IRB: 16-052.
Editorial acknowledgement
Legal entity responsible for the study
Anna Weiss.
Funding
This work was funded by a Breast Cancer Alliance Exceptional Project Award. The PELOPS trial was supported by Pfizer.
Disclosure
A.C. Weiss: Non-Financial Interests, Institutional, Advisory Board: Myriad, Merck, Abbvie. M.A.A. Fenton: Non-Financial Interests, Institutional, Other, Spouse Consultant: Astellas. L.C. Kennedy: Non-Financial Interests, Institutional, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Funding: Roche-Genentech, Puma Biotechnology. E. Mittendorf: Financial Interests, Personal, Advisory Board: Merck, BioNTech, AstraZeneca; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Institutional, Research Grant, I have a grant from SU2C funded by Roche/Genentech that supports the conduct of a clinical trial: Roche/Genentech; Financial Interests, Institutional, Coordinating PI, Gillead provides clinical trial support to my institution for a study that I am the PI on: Gillead; Financial Interests, Personal, Steering Committee Member: Roche/Genentech, BMS; Non-Financial Interests, Member of Board of Directors: American Society of Clinical Oncology; Non-Financial Interests, Advisory Role, I serve in an advisory role as a Komen Scholar: Komen for the Cure. O. Metzger: Financial Interests, Personal, Funding, Grant funding: Pfizer; Financial Interests, Personal, Other, Personal fees: Merck & Co, Oncoclicnicas. T.A. King: Financial Interests, Personal, Advisory Board, Compensated Services and Speakers Honoraria: Exact Sciences; Financial Interests, Personal, Leadership Role, Compensated service as faculty: PrecisCa Cancer Information Service. All other authors have declared no conflicts of interest.
Resources from the same session
242P - Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Presenter: Nicholas McAndrew
Session: Poster session 13
243P - Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Presenter: Luca Arecco
Session: Poster session 13
244P - Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Presenter: Yang Zhengjun
Session: Poster session 13
245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Presenter: Paolo Tarantino
Session: Poster session 13
247P - Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Presenter: Luiz Felipe de Almeida
Session: Poster session 13
248P - Impact of unilateral mastectomy with or without immediate breast reconstruction on vertebral alignment
Presenter: Jong-Ho Cheun
Session: Poster session 13
249P - Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Presenter: Laura Michel
Session: Poster session 13
250P - Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Presenter: Fresia Pareja
Session: Poster session 13